Unique ID issued by UMIN | UMIN000009358 |
---|---|
Receipt number | R000010995 |
Scientific Title | Development of oral taurine therapy for the treatment of MERRF |
Date of disclosure of the study information | 2012/11/19 |
Last modified on | 2018/10/09 15:52:59 |
Development of oral taurine therapy for the treatment of MERRF
Taurine therapy for MERRF
Development of oral taurine therapy for the treatment of MERRF
Taurine therapy for MERRF
Japan |
MERRF
Neurology |
Others
YES
To evaluate the efficacy of taurine to prevent disease progression of MERRF
Efficacy
-Frequency of seizure
-Clinical score of cerebellar ataxia
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Ten patients with MERRF having A8344G mutations in the mitochondrial DNA are enrolled in the study. Oral taurine (12g/d) is administered to the patients for 24 months to evaluate its effect on preventing epileptic symptoms and the progression of cerebellar ataxia.
16 | years-old | <= |
Not applicable |
Male and Female
Male and female patients over 16 years old
none
10
1st name | |
Middle name | |
Last name | Yutaka Ohsawa |
Kawasaki Medical School
Neurology
577 Matsusima, Kurashiki-city, Okayama 701-0192, Japan
086-462-1111
yosawa@med.kawasaki-m.ac.jp
1st name | |
Middle name | |
Last name | Yutaka Ohsawa |
Kawasaki Medical School
Neurology
577 Matsusima, Kurashiki-city, Okayama 701-0192, Japan
086-462-1111
yosawa@med.kawasaki-m.ac.jp
Department of Neurology, Kawasaki Medical School
Department of Neurology, Kawasaki Medical School
Other
Japan
Department of Biochemistry and Cell Biology, Institute of Development and Aging Sciences, Nippon Medical School
NO
川崎医科大学附属病院(岡山県)
2012 | Year | 11 | Month | 19 | Day |
Unpublished
Completed
2012 | Year | 11 | Month | 19 | Day |
2012 | Year | 12 | Month | 01 | Day |
2012 | Year | 11 | Month | 19 | Day |
2018 | Year | 10 | Month | 09 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010995